FDA sent a warning letter , dated Nov. 30, 2018, to Cao Medical Equipment Co., Ltd. detailing current good manufacturing practice (CGMP) violations agency inspectors observed during an inspection of the company s Langfang Industrial Zone, Langfang, Hebei facility, which was performed from JulOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.